Skip to main content
Premium Trial:

Request an Annual Quote

Biomarker Discovery Firm Biospect Raises $27M in Financing, Appoints CEO

NEW YORK, Oct. 21 (GenomeWeb News) - Biospect, a South San Francisco, Calif.-based startup developing systems for detecting biomarker patterns, today said it has received more than $27 million in equity financing from four venture capital firms: Advent Venture Partners, Prospect Venture Partners, Venrock Associates, and Versant Ventures. 

In addition, the company said that it has appointed Deborah Neff as president and CEO. Neff, who most recently held the position of worldwide president of BD Biosciences, will also serve on Biospect's board of directors.

Jim Tananbaum, chairman of Biospect and managing partner of Prospect Venture Partners, said the company plans to use the funding to commercialize its biomarker platform, which consists of proprietary separation, detection, and informatics technologies to detect patterns that characterize distinct biological states.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.